INTER MOUNTAIN CANCER GENOMICS

Brand Owner Address Description
INTERMOUNTAIN CANCER GENOMICS IHC Health Services, Inc. 36 South State Street, Suite 2200 Salt Lake City UT 84111 INTER MOUNTAIN CANCER GENOMICS;as to INTERMOUNTAIN;Medical services, namely, providing personalized drug therapy management programs to cancer patients based on the patient's genetic testing results; genetic testing for medical purposes; genetic testing for cancer diagnosis and treatment purposes; providing genetic sequencing and consulting services designed to provide cancer patients and oncologists with custom tailored information about the range of possible treatments and drug therapies for a particular cancer; providing information to patients and physicians to recommend cancer treatment and drug therapies based on the patient's genetic testing results; providing personalized drug therapy services for cancer patients; drug utilization review dispensing services, namely, identifying cancer drug therapies based on a patient's genetic testing results prior to dispensing medications; developing and managing comprehensive programs involving drug therapy and physician support services in the nature of providing consultation in the dispensing of prescription drugs for persons with particular cancers;CANCER GENOMICS;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in breast, gastric and prostate cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with cancer. The invention provides, inter alia, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.